ArticleInternational journal of molecular sciences2020
Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Neoadjuvant TACE combined with chemo-immunotherapy for giant triple-negative breast cancer: a case report.Frontiers in immunology · 2026Article
- Expression and role of PD-L1 and SOX10 in hepatocellular carcinoma.Translational cancer research · 2025Article
- Dissecting cross-lineage tumourigenesis under p53 inactivation through single-cell multi-omics and spatial transcriptomics.Clinical and translational medicine · 2025Article
- Role of the SOX family in cancer immune evasion: Emerging player and promising therapeutic opportunities.Medicine · 2025Review
- The Markers Auxiliary in Distinguishing Between Nodal Nevi and Melanoma Metastases.Current medicinal chemistry · 2025Review
- Article
- Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer.International journal of surgical pathology · 2024Article
- Potential biomarkers in breast cancer drug development: application of the biomarker qualification evidentiary framework.Biomarkers in medicine · 2024Review
- Clinical Significance of SOX10 Expression in Human Pathology.Current issues in molecular biology · 2023Review
- Characterization of GATA3 and Mammaglobin in breast tumors from African American women.Research square · 2023Article
- Characterization of GATA3 and Mammaglobin in breast tumors from African American Women.Archives of microbiology & immunology · 2023Article
- Article
- Review
- Breast metastasis from endometrial clear cell carcinoma: A case report and review of the literature.Frontiers in oncology · 2022Article
- Metastases to the Breast from Extramammary Nonhematological Malignancies: Case Series.International journal of general medicine · 2020Article
- Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSRY-related HMG-box 10 (SOX-10) is commonly expressed in triple negative breast cancer (TNBC). However, data on the biological significance of SOX-10 expression is limited. Therefore, we investigated immunhistological SOX-10 expression in TNBC and correlated the results with genetic alterations and clinical data.
methodsA tissue microarray including 113 TNBC cases was stained by SOX-10. Immunohistological data of AR, BCL2, CD117, p53 and Vimentin was available from a previous study. Semiconductor-based panel sequencing data including commonly altered breast cancer genes was also available from a previous investigation. SOX-10 expression was correlated with clinicopathological, immunohistochemical and genetic data.
resultsSOX-10 was significantly associated with CD117 and Vimentin, but not with AR expression. An association of SOX-10 with BCL2, EGFR or p53 staining was not observed. SOX-10-positive tumors harbored more often TP53 mutations but less frequent mutations of PIK3CA or alterations of the PIK3K pathway. SOX-10 expression had no prognostic impact either on disease-free, distant disease-free, or overall survival.
conclusionsWhile there might be a value of SOX-10 as a differential diagnostic marker to identify metastases of TNBC, its biological role remains to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.